ACE inhibitors in the treatment of heart failure: Special emphasis on ramipril

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 1, 1996, Pages 15-22

  Lubsen, Jacobus ^a  

^a SOCAR RESEARCH SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343430998     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bünning P. Kinetic properties of the angiotensin converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1987; 10 (Suppl 7): S31-S35.
2. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983; 2: 755-763.
3. Cleland JFG. Clinical perspective. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J 1995; 16: 153-159.
4. Cody RJ. Pharmacology of angiotensin-converting enzyme inhibitors as a guide to their use in congestive heart failure. Am J Cardiol 1990; 66: 7D-13D.
5. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986; 314: 1547-1552.
6. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
7. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 1986; 314: 349-358.
8. Crozier IG, Ikram H, Nicholls MG et al. Global and regional hemodynamic effects of ramipril in congestive heart failure. J Cardiovasc Pharmacol 1989; 14: 688-693.
9. DiBianco R, Shabetai R, Kostuk W et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677-683.
10. Erman A, Winkley J, Chen-Gal B et al. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991; 9: 1057-1062.
11. Feldman AM, Bristow MR, Parmley WW et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149-155.
12. Francis GS. Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55: 15A-21A.
13. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors: properties and side effects. Hypertension 1988; 37 (Suppl II): II-37-II-41.
14. Kholeif MA, Pringle S, Kesson E et al. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J Cardiovasc Pharmacol 1991; 18 (Suppl 2): 180-183.
15. Kostis JB. Curriculum in cardiology: angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J 1988a; 116: 1580-1591.
16. Kostis JB. Curriculum in cardiology: angiotensin converting enzyme inhibitors. H. Clinical use. Am Heart J 1988b; 116: 1591-1605.
17. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983; 67: 807.
18. Lenfant C. Cardiovascular news. Report of the task force on research in heart failure. Circulation 1994; 90: 1118-1123.
19. Lindsay HSJ, Ball SG. ACE inhibitors in the treatment of myocardial infarction. Rev Contemp Pharmacother 1996; 7: 39-53.
20. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertensive effect of ramipril. Br J Pharmacol 1992; 105: 771-772.
21. Linz W, Schölkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor ramipril in ischemic rat hearts. J Cardiovasc Pharmacol 1986; 8 (Suppl 10): S91-S99.
22. Linz W, Martorana PA, Schölkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990; 15 (Suppl 6): S99-S109.
23. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 1992a; 107: 970-975.
24. Linz W, Wiemer G, Schölkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992b; 24: 909-919.
25. Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am J Cardiol (accepted).
26. MacFate Smith W. Epidemiology of congestive heart failure. Am J Cardiol 1985; 55: 3A-8A.
27. Manthey J, Osterziel KJ, Roehrig N et al. Rampiril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems. Am J Cardiol 1987; 59: 171D-175D.
28. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transpl 1993; 13: S107-S112.
29. Packer M. Treatment of chronic heart failure. Lancet 1992; 340: 92-95.
30. Packer M, Medina N, Yushak M. Correction of dilutional hyponatraemia in severe heart failure by converting-enzyme inhibition. Ann Intern Med 1984; 100: 782.
31. Packer M, Carver JR, Rodeheffer RJ et al. for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
32. Pfeffer MA, Braunwald E, Moyé LA et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
33. Poole-Wilson PA. Chronic heart failure: causes, pathophysiology, prognosis, clinical manifestations, investigations. In: Julian DJ, Camm AJ, Fox KM et al., eds. Diseases of the heart. London: Baillière Tindall, 1989: 48-57.
34. Rothman KJ. Modern epidemiology. Boston: Little Brown & Co, 1986.
35. Schocken DD, Arrieta MI, Leaverton PE et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-306.
36. Scholz H, Meyer W. Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation 1986; 73: III-99-III-108.
37. Sharpe N, Murphy J, Smith H et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; i: 255-259.
38. Smith TW, Braunwald E, Kelly RA. The management of heart failure. In: Braunwald E, ed. Heart disease - a textbook of cardiovascular medicine. Fourth edition. Philadelphia: Saunders, 1992: 464-520.
39. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
40. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
41. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
42. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
43. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
44. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
45. Todd PA, Benfield P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39: 110-135.
46. Uretsky BF, Jessup M, Konstam MA et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990; 82: 774-780.